Bausch + Lomb Receives Health Canada Approval for enVista Envy Full Visual Range IOL
Health Canada has approved Bausch+Lomb's enVista Envy full visual range IOL. This is the first regulatory approval of the new lens, which is designed to offer a full range of vision with dysphotopsia tolerance on the enVista IOL platform.
“enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” Luc Bonnefoy, president, Global Surgical, Bausch + Lomb, said in a company news release. “This first premium IOL on the enVista platform follows the US launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”
A multicenter, randomized, and controlled clinical trial demonstrated excellent long-term outcomes with the enVista Envy IOL in Canada.1 On average, 93% of patients reported little to no bothersomeness for dysphotopsia (glare, halo, starbursts), touting an impressive tolerance profile overall. Additionally, 94% of patients reported little to no difficulty viewing close objects, while delivering excellent distance vision spectacle-free post-surgery with 4 diopters of continuous visual range, according to B+L.
The enVista Envy features ActivSync Optic Intelligent Energy Distribution, optimizing vision in every lighting condition, and ClearPath technology, which helps reduce light scattering. Low-Cyl toric technology allows the enVista Envy toric lens to simultaneously treat presbyopia and low amounts of astigmatism (0.9D IOL Plane - Canada), while offering more precision with 0.5D steps (or less) throughout the cylinder range.
enVista Envy IOLs will be commercially available in Canada mid-June. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the US and Europe.